Lazard Upgrades Valeant Pharma (VRX) to Hold
More News related to VRX
- Valeant Reports Encouraging End of Treatment Results with Taribavirin at Treatment Week 48 in Phase IIb Study
- Notable Mergers and Acquisitions of the Day 11/14: AGO, BA, VRX
- Valeant Pharmaceuticals (VRX) Acquires DermaTech for AU$19M
- Valeant Pharmaceuticals Acquires DermaTech
- Valeant Pharmaceuticals to Present at Lazard Capital Markets 5th Annual Healthcare Conference
More News related to Upgrades
- Post Properties (PPS) Announces Reduction In Quarterly Dividend To 20c, CIO Departure and New Stock Buyback Of Up To $200M
- Roberts Realty Investors (RPI) Increases Stock Repurchase Program
- United American Healthcare (UAHC) Approves $1 Million Stock Buyback
- Quidel Corporation (QDEL) Extends Current Stock Buyback Plan
- Quidel (QDEL) Adds $25M to Buyback Program
Lazard Capital upgrades Valeant Pharmaceuticals (NYSE: VRX) from Sell to Hold.
Valeant Pharmaceuticals International, a specialty pharmaceutical company, engages in the development, manufacture, and marketing of a range of pharmaceutical products.
Related Categories
UpgradesStocks Mentioned
+0.83Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
